China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Add as a preferred source on Google
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
